Seeking Alpha
18 Jun 2026, 19:41 UTC · 17w ago
Impact · against what's priced in
Spero Therapeutics receives a significant value inflection with the FDA approval of Utebzi and a corresponding revenue stream from GSK. GSK gains a first-in-class oral carbapenem, though the impact is marginal relative to its scale.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has approved Utebzi, the first oral carbapenem for complicated urinary tract infections.
More positive than 99% of claims this week
Spero Therapeutics is eligible for milestone payments and royalties from GSK, with potential annual earnings of ~$50m.
So whatDirect revenue streams and milestones provide concrete valuation support and improve cash flow.
Continue reading
5 related stories
FDA approval of Utebzi unlocks milestone payments and royalties from GSK with potential annual earnings of ~$50m, while a runway into 2028 mitigates dilution risk.
Read from the article alone
No priced-in read yet
The company adds a first-in-class oral carbapenem for complicated urinary tract infections to its portfolio.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 94% of claims this week
Spero maintains a low burn rate with a funding runway extending into 2028.
So whatExtended cash runway reduces the immediate risk of dilutive financing rounds.
More positive than 81% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
FDA approval of Utebzi provides a path to milestone payments, royalties, and long-term funding runway.
More positive than 68% of ticker scores this week
The company received FDA approval for a new oral carbapenem for urinary tract infections.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
2h ago
−42.2%
Price is moving against the score
$1.22 vs $2.11 close before publication (Jun 17) · not market-adjusted
SPRO chart →−2.9%
Price is moving against the score
$50.63 vs $52.15 close before publication (Jun 17) · not market-adjusted
GSK chart →
